Quarterly report pursuant to Section 13 or 15(d)

SEGMENT INFORMATION (Tables)

v3.20.2
SEGMENT INFORMATION (Tables)
 9 Months Ended
Sep. 30, 2020
Segment Reporting [Abstract]  
Schedule of segment reporting information
The following table presents information by reportable operating segment for the three and nine months ended September 30, 2020 and 2019 (in thousands):
Consumer Products
Segment		 Specialty Pharmaceutical Segment Consolidated Totals
Three months ended September 30, 2020:
Product sales, net $ 5,564  $ —  $ 5,564 
Gross profit $ 2,458  $ —  $ 2,458 
Research and development expense 119  293  412 
Selling, general and administrative expense 5,188  9  5,197 
Operating loss $ (2,849) $ (302) $ (3,151)
Three months ended September 30, 2019:
Product sales, net $ 12,603  $ —  $ 12,603 
Gross profit $ 8,428  $ —  $ 8,428 
Research and development expense 437  1,107  1,544 
Selling, general and administrative expense 8,646  11  8,657 
Operating loss $ (655) $ (1,118) $ (1,773)

Consumer Products
Segment		 Specialty Pharmaceutical Segment Consolidated Totals
Nine months ended September 30, 2020:
Product sales, net $ 19,230  $ —  $ 19,230 
Gross profit $ 8,788  $ —  $ 8,788 
Research and development expense 575  2,092  2,667 
Selling, general and administrative expense 19,178  71  19,249 
Operating loss $ (10,965) $ (2,163) $ (13,128)
Nine months ended September 30, 2019:
Product sales, net $ 44,368  $ —  $ 44,368 
Gross profit $ 30,938  $ —  $ 30,938 
Research and development expense 1,815  2,759  4,574 
Selling, general and administrative expense 36,230  31  36,261 
Operating loss $ (7,107) $ (2,790) $ (9,897)